In an effort to clear persistent HIV infection and achieve a durable therapy-free remission of HIV disease, extensive pre-clinical studies and early pilot clinical trials are underway to develop and test agents that can reverse latent HIV infection and present viral antigen to the immune system for clearance. It is, therefore, critical to understand the impact of latency-reversing agents (LRAs) on the function of immune effectors needed to clear infected cells. We assessed the impact of LRAs on the function of natural killer (NK) cells, the main effector cells of the innate immune system. We studied the effects of three histone deacetylase inhibitors [SAHA or vorinostat (VOR), romidepsin, and panobinostat (PNB)] and two protein kinase C agonists [prostratin (PROST) and ingenol] on the antiviral activity, cytotoxicity, cytokine secretion, phenotype, and viability of primary NK cells. We found that ex vivo exposure to VOR had minimal impact on all parameters assessed, while PNB caused a decrease in NK cell viability, antiviral activity, and cytotoxicity. PROST caused non-specific NK cell activation and, interestingly, improved antiviral activity. Overall, we found that LRAs can alter the function and fate of NK cells, and these effects must be carefully considered as strategies are developed to clear persistent HIV infection.
CD4 + T cells, with the goal of reducing the reservoir size through viral cytopathic effects (CPE) or immune-mediated clearance. However, recent in vitro experiments demonstrated that proviral reactivation alone did not result in viral CPE, and the autologous HIV-1 specific CD8
+ T cells of patients were unable to clear reactivated cells (4) . Clearly, the capacity of the host immune system to recognize and kill infected cells upon reactivation requires closer evaluation.
Histone deacetylase (HDAC) inhibitors and protein kinase C (PKC) agonists are two promising classes of latency-reversing agents (LRAs) that are undergoing extensive testing in in vitro models and in initial pilot clinical trials to reactivate latent HIV-1 infection. HDAC inhibitors were developed as anticancer drugs as HDACs play important roles in epigenetic and non-epigenetic transcriptional regulation, inducing apoptosis and cell cycle arrest (5) . In the context of HIV-1 reactivation, HDAC inhibitors induce transcription at the HIV-1 long terminal repeat (LTR) (6) (7) (8) (9) . PKC agonists induce latent viral expression though NF-κB signaling (10) . Members of these two LRA classes have demonstrated efficacy in inducing HIV-1 expression in cells from patients on ART in vivo and in vitro (9, (11) (12) (13) (14) (15) (16) . However, as both histone deacetylation and signaling through NF-κB may impact the function of diverse cell populations, the effect of LRAs beyond latently infected cells must be carefully evaluated.
The influence of LRAs on cytotoxic T-lymphocytes (CTL) has recently been assessed. In one in vitro study, selected HDAC inhibitors caused a negative impact on CTL effector function (17) , although in both this study and in another study that focused on vorinostat (VOR) (18) , little effect of a pharmacologically relevant exposure to VOR was seen. CD8
+ T cells are a well-studied and crucial effector cell population contributing to target cell clearance after viral reactivation. However, other effector subsets may also play an important role, including cells from the innate immune system. Natural killer (NK) cells are the main effectors of the innate immune response. NK effector function is elicited immediately upon recognition of activating ligands without prior exposure to the infected cell or to viral antigens, resulting in direct lysis of target cells and/or promotion of antibody-dependent cellular cytotoxicity (ADCC) (19) . In addition, NK activity has been associated with HIV post-treatment control of viremia after treatment interruption (20) , ADCC has been correlated with protection in a recent HIV-1 vaccine trial (21) and innate immune cell responses were correlated with HIV-1 DNA decline during panobinostat (PNB) treatment in vivo (22) . Thus, multiple lines of evidence suggest the relevance of NK cells in the clearance of persistent HIV-1 infection.
In the present study, we aim to better understand the impact of LRAs on the innate immune system, and specifically on NK cells. LRAs might impact the capacity of NK cell to clear infected cells in at least two ways: (i) through a direct impact on immune effector cells, causing activation, toxicity, or modifying receptor expression and cytotoxicity capacity or (ii) affecting the expression of ligands in the target population modifying effector recognition and subsequent clearance. Herein, we analyze both the direct impact of candidate compounds from two promising LRA classes on NK cells, and the effects on ligand expression on target cells ex vivo, as a means of informing HIV-1 eradication strategies making use of these agents in future pilot clinical trials.
MaTerials anD MeThODs cell samples
Peripheral blood mononuclear cells (PBMC) were obtained by Ficoll gradient from buffy coats of HIV-1 negative healthy donors, under approval of the UNC Biomedical Institutional Review Board. NK and CD4
+ T cells were magnetically isolated from the PBMCs by negative selection (StemCell Technologies, Vancouver, BC, Canada). The NK cell enrichment antibody cocktail included monoclonal antibodies against CD3, CD4, CD14, CD19, CD20, CD36, CD66b, CD123, HLA-DR, and glycophorin A. The CD4 + T cell enrichment antibody cocktail included specific antibodies against CD8, CD14, CD16, CD19, CD20, CD36, CD56, CD66b, CD123, TCR-γ/δ, and glycophorin A. After isolation, NK cells were cultured in Iscove's Modified Dulbecco's Medium (IMDM) supplemented with 10% heat inactivated bovine serum and 5% penicillin plus streptomycin (cIMDM), including or not the different LRAs at the appropriate concentrations for 24 h. Then, cells were washed and functional assays performed.
ethics statement
Study participants provided written informed consent under a protocol that was approved by the UNC Biomedical Institutional Review Board.
latency-reversing agents
The compounds comprising our LRA panel were provided, and stocks prepared, by the CARE Pharmacology Core of the University of North Carolina. VOR was donated by Merck, and romidepsin (RMD) and PNB obtained from Selleckhem. For all three, a 10 mM stock was prepared in DMSO, and further diluted with IMDM to a working stock concentration of 25 μM (VOR) or 5 μM (RMD and PNB). Prostratin (PROST) was purchased from Cayman Chemical (Ann Arbor, MI, USA) in an ethanol solution, which was lyophilized and reconstituted with DMSO to a concentration of 5 mM, and further diluted in plain IMDM to a working stock solution of 25 μM. Ingenol (ING) 3-20 dibenzoate was obtained from Santa Cruz Biotechnology; stock solution was prepared in DMSO at a concentration of 1 mM and diluted to working stock concentration of 25 μM with nonsupplemented IMDM. All stocks and working solutions were stored at −20°C and used avoiding repeated freezing-thawing cycles. LRA concentrations used in the experiments were selected based on pre-clinical data to reflect the potential physiological concentration (23) (24) (25) . VOR was used at a concentration of 335 nM, RMD at 10 nM, PNB at 20 nM, PROST at 1000 nM, and ING at 100 nM. If physiologic (in vivo) data were not available for selecting a concentration, concentrations were chosen to reflect dosing previously shown to be effective in HIV-1 reactivation in ex vivo studies (11, 26, 27) . In addition, a lower and a higher dose of the one considered physiological were tested in some experiments to determine if there was a dose-dependent relationship.
Viral inhibition assays

CD4
+ T cells were isolated by negative selection in parallel to NK cells from each donor. Isolated CD4 + T cells were activated during 24 h with 2 μg/mL PHA (Sigma Aldrich, St Louis, MO, USA) and 60 U/mL IL-2 (Peprotech, Rocky Hill, CT, USA). Cells were then infected with the JR-CSF viral strain by spinoculation for 90 min at 2500 rpm. After spinoculation, cells were extensively washed to remove free virions and 50,000 CD4 + T cells were plated in triplicate for each condition in a 96-well plate. NK cells, previously exposed to LRAs or not (reference control), were added to the wells in an effector:target (E:T) ratio of 1:1, and left in culture for 7 days in cIMDM with 5 U/mL IL-2, with a media change at day 4. Viral production was assessed in the supernatant by p24 ELISA (ABLinc, Rockville, MA, USA), and percentage of viral inhibition of the different conditions was compared to inhibition from untreated NK cells. To assess the impact of LRAs on cell population proportion, we performed FACS analysis of the cells at the end of the viral inhibition assay. Cells were harvested and surface stained with CD3-PerCP, CD4-FITC, and CD56-PE (BD). cytotoxicity, iFn-γ Production, and non-specific activation assays
Natural killer cytotoxicity and IFN-γ production were analyzed in co-cultures of primary NK cells and K562 cells (an NK-sensitive target cell line that lacks MHC-I molecules) with and without previous exposure of the NK cells to individual LRAs from our panel. Cytotoxicity was assessed by analyzing the expression of the degranulation marker CD107a, a reliable marker of NK cell cytotoxic activity (28) . A total of 100,000 NK cells were co- 
statistical analysis
Statistical analyses were performed using GraphPad Prism version 6.07 (GraphPad Software, La Jolla, CA, USA). Data are presented either as raw values or fold change (FC) normalized to untreated NK cells for each of the experiments. Statistical significance was determined with a Wilcoxon matched-pairs signed rank test. resUlTs nK cell antiviral activity improves after Prostratin exposure but it is impaired after Panobinostat and ingenol Treatment Viral inhibition capacity of NK cells was tested in autologous cell systems, using NK and CD4 + T cells from the same donor. The average purity of NK cells after isolation -measured as To elucidate the mechanisms by which some drugs altered NK cell antiviral activity, we investigated the direct impact of exposure to such drugs on NK cytotoxicity, IFN-γ production, viability, activation, and receptor expression. In addition, at the end of the viral inhibition assay, the cells present in the cultures were stained for NK cell markers (CD56) and T cell markers (CD3 and CD4). Interestingly, we found that proportion of NK cells increased following PROST exposure (153%, SEM = 14.0, p = 0.03), while the frequency of CD4 cells within the CD3 (Figure 2A) . We observed a general trend toward a decrease in viability after exposure to all drugs (p = 0.02) except for ING (p = 0.53), but the impact of RMD and PNB was more pronounced, with a mean FC of 2 and 2.5 for RMD and PNB, respectively, compared to VOR and PROST (mean FC = 1.3 and 1.2, respectively) ( Figure 2B ). In addition, exposure to increasing concentrations of RMD and PNB decreased cell viability in a dose-dependent manner, while viability of NK cells was not reduced following exposure to higher concentrations of VOR, PROST, or ING ( Figure S4 in Supplementary Material). As the observed dead cell numbers were high, we compared the viability of untreated NK cells right after isolation and after 24 h in culture. We observed an increase of the apoptotic population (measured as Annexin V+) from 14.8 to 32%. This high rate of cellular death may be due to the lack of IL-15 or IL-2 in the culture.
lra impact on nK cell-Mediated cytotoxicity
Natural killer cytotoxicity was measured by analyzing the expression of CD107a after co-culture with K562 cells (Figure 3A) . Exposure to a physiologically relevant concentration of RMD, PNB, and ING impaired the cytotoxic capacity of NK cells, as shown by a significant decrease in the proportion of CD56 + CD107a + cells (p < 0.0001). However, VOR and PROST did not have a significant impact on NK cytotoxic function ( Figure 3B) . The observed impairment in NK cell cytotoxic function caused by RMD, PNB, and ING was not due to a direct effect on the viability of NK cells, as we checked in cytotoxic function assays, including a viability stain (Annexin V-FITC and 7-AAD, n = 4 donors; data not shown).
We further analyzed whether the impairment in cytotoxic activity was dose dependent. NK cell cytotoxicity showed a dose-dependent reduction after exposure to RMD and PNB, and to some extent to VOR. Interestingly, a higher dose (1000 nM) of ING showed a slight improvement in NK cytotoxic function compared to 100 nM ( Figure S5 in Supplementary Material).
Panobinostat and Prostratin impair iFn-γ secretion
Interferon-gamma secretion is an antiviral mechanism employed by NK cells and leads to recruitment and modulation of the activity of other effector cells, including CD8
+ T cells (29) . We analyzed IFN-γ production after a 4-6 h culture with K562 target cells ( Figure 4A ). FACS analysis after intracellular IFN-γ staining 
PKc agonists cause non-specific nK cell activation
To measure non-specific NK cell activation caused by exposure to LRAs, expression of CD69, CD107a, and IFN-γ was measured in the absence of target cells or any other stimulus. Exposure to all drugs caused non-specific activation as measured by CD69 expression (p = 0.01), although activation was much greater after treatment with PROST and ING (27-and 14-fold, respectively). Among the HDACi tested, PNB led to an increase in CD69 expression of nearly 10-fold, while VOR and RMD only produced 1.5-and 2.2-fold increase. In addition, exposure to the PKC agonist PROST caused marked increase in CD107a, while the increase caused by ING was more variable (p = 0.01 and p = 0.06, respectively; Figure 5 ). IFN-γ production in the absence of target cells was also assessed, and no change was observed after exposure to any of the LRA (data not shown). Figure S6 in Supplementary Material show these results as raw data.
expression of activating receptors on nK cells is Downregulated by exposure to PnB
Natural killer cells express a wide variety of receptors that enable them to differentiate infected or tumor cells from healthy cells. These include inhibitory, activating, adhesion, and cytokine receptors. The balance of these signals determines whether the NK cell becomes activated or not (30) . For this study, we analyzed the expression of activating receptors that have been identified to be important for antiviral activity of NK cells. These included CD16, NKG2D, DNAM-1, NKp30, NKp44, and NKp46 (31). 
impact of lras on nK ligand expression in resting cD4
+ T cells
We analyzed by flow cytometry the expression of some ligands on target cells that either trigger NK activation or initiate inhibitory NK signaling by binding to NK inhibitory receptors. The activating ligands included NTB-A, which binds NTB-A on the NK cell surface and leads to activation and secretion of interferon-γ, CD48, which binds 2B4, ULBP-1 and -2, ligands that bind NKG2D and that have been demonstrated to be upregulated in the setting of HIV-1 infection by the viral protein vpr (32) , and CD155, a NK ligand that binds DNAM-1 on NK cells and induces activation (33) . The inhibitory included HLA-E In sum, exposure to PKC agonists PROST and ING significantly increased two inhibitory NK ligands (HLA-E and HLA-Bw4) and one activating ligand (CD155) on the cell surface of primary CD4 + T cells, while HDACi exposure had little effect on NK ligand expression on resting CD4
+ T cells (Figure 7) .
DiscUssiOn
For successful implementation of the HIV eradication strategy of latency reversal and clearance, LRAs doses and administration regimens must be selected so that they induce viral antigen expression in latently infected cells but do not interfere with the clearance function of immune effector cells. In this study, we have evaluated the impact of five LRAs on NK cell function. Overall, we observed a heterogeneous effect of the different LRAs evaluated, differing even within each drug class. VOR did not have any significant effect on any of the parameters of NK cell function or viability, while exposure to the other HDACi tested, RMD and PNB, had deleterious effects. Particularly, PNB caused a significant decrease in cytotoxicity, antiviral activity, activating receptor expression, and cytokine secretion of NK cells, along with a decrease in viability. A similar trend was observed for RMD, but milder that the observed with PNB. PKC agonists induced expression of some markers of activation in NK cells and, remarkably, PROST exposure lead to an improvement in antiviral activity.
To our knowledge, no studies of the impact of PNB or PKC agonists on NK cell function have been performed. A previous study reported VOR suppression of NK cell cytolytic activity by impairing granule exocytosis and decreasing expression of activating receptors (34) . However, a 96-h incubation with the drug was carried out in those experiments, which exceeds the in vivo pharmacokinetic exposure to VOR, cleared in less than 6 h (35). On the contrary, we did not observe any negative impact of VOR on NK cell function. Clinical treatment with RMD in patients with cutaneous T-cell lymphoma induced a decrease of NK cell cytolytic activity, similar to our ex vivo results, although interestingly the activity was restored after stimulation with a toll-like receptor agonist (36) .
Here, we observed that PNB exposure caused a decrease in the antiviral activity of NK cells. This impairment in viral inhibition was likely due to the reduction in cytotoxicity and IFN-γ production that we also observed, as well as the down-modulation of important activating receptors, such as NKG2D, on the surface of the NK cells. In addition, PNB decreased NK cell viability, so at least part of the decreased antiviral activity observed in the viral inhibition experiments could be due to an actual reduction of number of NK cells in culture, with a consequent reduction in E:T cell ratio. In fact, using our whole dataset, we found that both cytotoxicity and cell viability correlated significantly with a decrease in antiviral activity ( Figure S8 in Supplementary Material). PNB has been shown in a study to be the most potent of all HDAC inhibitors (37) , and could represent a very promising option for HIV reactivation. However, our in vitro results point out the potential deleterious effects that PNB can have on NK cell function, and this should be monitored in future clinical studies. Interestingly, the recent in vivo pilot clinical trial with PNB observed that patients with more pronounced proviral DNA decline during PNB treatment had a higher frequency of NK cells (22) , suggesting that the function of the innate immune system should be monitored during latency reversal and clearance studies.
On the other hand, we observed an improvement in NK antiviral activity after exposure to PROST. This observation could be due to the increase in NK activation upon culture with the drug; however, it is also possible that PROST remained attached to cellular membranes despite washing after drug exposure as has previously been suggested (38) , leading to blunted HIV infection in target cells. When we analyzed the cell composition of the cultures after a 7-day viral inhibition assay, we consistently observed that in the cultures where NK cells were exposed to PROST, the CD3 − CD56 + subset was increased compared to all the other conditions, with an especially marked increase in the CD56 bright population, while the proportion of cells expressing CD4 within the CD3
+ population was decreased. Moreover, exposure to PROST upregulated the expression of NKG2D, which is a NK cell activating receptor known for its importance in NK cell antiviral activity (39, 40) . Thus, the increase in antiviral activity observed after PROST exposure was most likely due to a combination of several effects, including changes in both the target population and in the effector population. This may have interesting implications for in vivo HIV-1 eradication strategies in which PKC agonists might simultaneously induce several desirable effects: reactivation of latently infected cells, inhibition of viral replication, and enhancement of the antiviral effect of NK cells. ING, the other PKC agonist tested in our experiments, did not have such a marked effect in any of the functional characteristics analyzed, but we did observe upregulation of NKG2D and some activation measured by CD69. Beyond the specific characteristics of each of these components of the PKC agonist family, a possible reason for the difference in the magnitude of the effect observed with PROST and ING could be the dose of each drug used in our experiments. In fact, when a higher dose (1 μM) of ING was used for the viral inhibition experiments, an improvement in NK cell antiviral activity was observed (mean of twofold compared to untreated NK cells, Figure S9 in Supplementary Material). However, we also observed a decrease in IFN-γ production when NK cells were exposed to PKC agonists. This conflicts with our observations of the increase of the CD56 bright population, given that generally CD56 dim subpopulations are more cytotoxic, while CD56 bright are able to produce IFN-γ (41). We also observed a decrease in CD16 expression on NK cells treated with PROST, which in this case would correlate with the increase in the CD56 bright subpopulation, as CD16 is expressed largely in CD56 dim subsets. Down-modulation of CD16 is concerning given that ADCC is mediated by antibody engagement to this receptor, and further study is required to determine whether this decrease in expression has functional consequences. Our experiments were performed using unstimulated NK cells, with the aim of recapitulating in vivo exposure to LRAs. However, for immunotherapeutic purposes, an alternative strategy involves ex vivo stimulation and expansion of NK cells, with the intention of improving their cytotoxic potential. Susceptibility of these expanded cells to LRAs may differ from what we have observed in non-stimulated cells, as it has been already shown for impact on CTL (17) . In fact, we observed a reduction in K562 target cell lysis when expanded NK cells were exposed to PROST (data not shown). On the contrary, and although we did not observe relevant impact of VOR on NK cell function, Schmudde et al. reported an impairment of NK cell degranulation by VOR exposure when cells were not stimulated, but no impact if NK cells were previously stimulated with IL-2 (42) .
In addition to investigating the direct impact of LRAs on NK cells, we analyzed the impact of exposure to these agents on target cells relevant for HIV infection (resting CD4 + T cells) to assess expression of surface ligands that would render them more susceptible to NK cell recognition and clearance. Overall, we did not observe a striking effect on ligand expression on CD4 + T cells, with the exception of a modest increase in HLA-E and BW4 (inhibitory ligands), and CD155 (an activating ligand) when cells were exposed to PKC agonists. Different observations have been reported from oncology studies, where it has been consistently reported that HDACi upregulate the expression of NKG2D ligands on tumor cells (43) (44) (45) (46) , helping their recognition by innate immune system. On the other hand, it has also been seen that HDACi can down-modulate the expression of NKp30 ligands on tumor cells, reducing NKp30-dependent effector functions of NK cells (47) .
To achieve clinically significant reversal of HIV-1 latency, several studies suggest that combinations of mechanistically different LRA will be needed (48) (49) (50) . Our results add an additional factor to consider when designing an adequate LRA combination, as not only reactivation potency should be taken into account but also the impact that each of the drugs have on immune effector function. Thus, if a certain LRA is selected to be used because of its potency for reactivating the reservoir but it has shown to cause an impair in immune function, the second component of the LRA combination ideally should have proven to cause an improvement to some extent in the effector activity. The optimum situation for cure strategies would be finding compounds that simultaneously can disrupt latency and boost the immune response, and some agents with these capabilities are beginning to be described (51) .
In summary, we have evaluated ex vivo the impact of five different latency-reversing agents on the effector function, phenotype, and viability of NK cells. This is of clinical relevance given the necessity of a potent immune response after reactivation of the latent HIV reservoir in order to achieve viral eradication. We have found a heterogeneous effect of the different agents studied, highlighting the lack of impact of VOR, the negative effects of PNB and RMD, and the potential beneficial impact of PKC agonists. Impact of LRA on immune function should be considered when designing LRA combinations to reactivate the latent HIV-1 reservoir. This is the first study to address the impact of LRAs on innate immune functions in the context of HIV-1 eradication, and demonstrate the importance of further evaluation of NK cell function. However, in vitro results might differ from in vivo effects. Our analysis of the effect of LRAs on NK cell function is, of necessity, only a preliminary one. In clinical trials, multiple doses of LRAs will be given over time, a phenomenon that is more difficult to model. Thus, innate immune function should be evaluated in HIV-1 positive patients undergoing latency reversing therapy.
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